Published in Drug Week, June 24th, 2005
Eshelman did not sell any of the shares of common stock acquired through the option exercises.
As a result of the purchase of these shares, Eshelman now owns approximately 5.36 million shares of PPD common stock, or approximately 9.4% of the company's outstanding common shares and remains one of PPD's largest shareholders.
As a global provider of discovery and development services and products for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week